VEGFA and alveolar soft part sarcoma: Based on the single-arm clinical trial of NCT02636725, the anti-VEGF inhibitor (axitinib) plus anti-PD-1 antibody (pembrolizumab) had antitumor activity in ASPS patients (the mPFS was 12.4 months, the ORR was 54.5%, and the CBR was 72.7% at 3 months) (Wilky et al., 2019).